(Q39748254)

14 September 2017

title

Antitumor activity of anti-C-ERC/mesothelin monoclonal antibody in vivo (English)

1 reference

14 September 2017

1 reference

Koichi Inami

1

1 reference

14 September 2017

Masaaki Abe

2

1 reference

14 September 2017

Kazuyoshi Takeda

3

1 reference

14 September 2017

Yoshiaki Hagiwara

4

1 reference

14 September 2017

Masahiro Maeda

5

1 reference

14 September 2017

Tatsuya Segawa

6

1 reference

14 September 2017

Masafumi Suyama

7

1 reference

14 September 2017

Sumio Watanabe

8

1 reference

14 September 2017

Okio Hino

9

1 reference

14 September 2017

publication date

9 December 2009

1 reference

14 September 2017

1 reference

14 September 2017

volume

101

1 reference

14 September 2017

issue

4

1 reference

14 September 2017

page(s)

969-974

1 reference

The epidemiology of mesothelioma

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01463.X

Malignant pleural mesothelioma: surgical roles and novel therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01463.X

Incidence and survival of mesothelioma in Osaka, Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01463.X

Mapping and determination of the cDNA sequence of the Erc gene preferentially expressed in renal cell carcinoma in the Tsc2 gene mutant (Eker) rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01463.X

Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01463.X

Mesothelin: a new target for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01463.X

Molecular cloning and expression of megakaryocyte potentiating factor cDNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01463.X

Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01463.X

Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01463.X

Diagnostic biomarker of asbestos-related mesothelioma: example of translational research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01463.X

Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01463.X

Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01463.X

Soluble mesothelin-related protein--a blood test for mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01463.X

Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01463.X

Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01463.X

Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01463.X

Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01463.X

Tumor-directed radiation and the immunotoxin SS1P in the treatment of mesothelin-expressing tumor xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01463.X

Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01463.X

Establishment of novel mAb to human ERC/mesothelin useful for study and diagnosis of ERC/mesothelin-expressing cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01463.X

Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01463.X

Improved method for pepsinolysis of mouse IgG(1) molecules to F(ab')(2) fragments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01463.X

The development of autoimmunity in C57BL/6 lpr mice correlates with the disappearance of natural killer type 1-positive cells: evidence for their suppressive action on bone marrow stem cell proliferation, B cell immunoglobulin secretion, and autoimm

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01463.X

Fc receptors as targets for immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01463.X

Mesothelin is not required for normal mouse development or reproduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01463.X

Combination antibody-based cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01463.X

Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01463.X

Surgery for pancreatic cancer: recent controversies and current practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01463.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01463.X

Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01463.X

Mesothelin-family proteins and diagnosis of mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01463.X

10.1111/J.1349-7006.2009.01463.X

21 January 2018

Identifiers

DOI

1 reference

14 September 2017

1 reference